Jaume Mora Graupera
Jefe de Grupo Senior
Research group
Professional network profiles
Last Publications
- Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano-Escuder P, Pérez-Jaume S, Garcia-López M, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. CANCER RESEARCH . 85(22): 4485-4503.
- Prada-Varela E, Táboas-Outón P, Andrades E, Gomez-Gonzalez S, Mateo-Lozano S, Cebrià A, Berenguer-Molins P, Perera-Bel J, Arcon JP, Saen-Oon S, Díaz L, Gay M, Folch-I-Casanovas I, Odena A, Vilaseca M, Rovira Q, García-Gerique L, Rodriguez E, Rovira-Zurriaga C, Rodrigues G, Carcaboso AM, Avgustinova A, Hernandez-Muñoz MI and Mora J PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma. NATURE COMMUNICATIONS . 16(1): 9816-9816.
- Hernandez-Muñoz MI, Cuervas I, Prada-Varela E, Pulecio J, Gimeno R, Andrades E, Gomez-Gonzalez S, Berenguer-Molins P, Acedo-Terrades A, Perera-Bel J, Bódalo-Torruella M, Nonell L, Pérez E, Grases D, Mata C, Yélamos J, Richaud-Patin Y, Vidal E, Cuartero Y, Le Dily F, Suñol M, Manzanares-Quintela A, Raya A and Mora J EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma NATURE COMMUNICATIONS . 16(1): 9427-9427.
Projects
- Project name:
- FIGH4MB_Establishment of the first preclinical genetic mouse models of Group 4 Medulloblastoma.
- Leader
- Jaume Mora Graupera
- Funding entities:
- Fight Kids Cancer
- Code
- PFE00151
- Starting - finishing date:
- 2025 - 2028
- Project name:
- ADVANCED THERAPIES (RICORS-TERAV)
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- RD24/0014/0006
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
News
-
Researchers Find the Cell of Origin of Ewing Sarcoma
Researchers suspect that the genetic alteration that triggers the mechanisms that generate this type of cancer occurs during embryonic development
-
Dr. Jaume Mora receives the IV FERO Dr. Baselga Grant to promote new therapies against pediatric cancer
The scientific director of the Pediatric Cancer Center Barcelona receives a grant of €300,000 for a three-year project aimed at developing more effective and less toxic treatments for childhood cancer.
-
A study led by SJD identifies new therapeutic targets for Ewing sarcoma
The study identifies the demethylases KDM6A and KDM6B as essential collaborators of the fusion protein EWSR1::FLI1, responsible for the epigenetic reprogramming that drives tumor growth.
More activities
-
Defensa tesi doctoral: Pablo Táboas Outón
Auditori Plaza · Hospital Sant Joan de Déu and online
-
Defensa tesi doctoral: Irene Cuervas Oliveras
Auditori Plaza · Hospital Sant Joan de Déu
-
Defensa tesi doctoral: María Sánchez Jiménez
Auditori Plaza · Hospital Sant Joan de Déu and online
